Fiocruz granted royalty-bearing license from iBio

IBio, which focuses on the development and commercialization of novel plant-made products for the prevention and treatment of serious infectious diseases, has granted a commercial, royalty-bearing license to Fiocruz/Bio-Manguinhos of Brazil to develop, manufacture and sell certain vaccines based upon the company's proprietary technology. Financial terms of the deal were not disclosed, but investors drove iBio's stock up 19 percent to close at $5.85 on Tuesday, DelawareOnline notes. The license covers the nations of Latin America, the Caribbean and Africa.

Fiocruz/Bio-Manguinhos will invest more than $6 million to bring the first product, a new yellow fever vaccine, through Phase I clinical trials. Product development will be performed through a commercial collaboration that involves iBio, Fiocruz/Bio-Manguinhos and the Fraunhofer USA Center for Molecular Biotechnology (FCMB).

IBio's technology infuses genes into plants to create proteins for vaccines and was developed at the FCMB. The companies are involved in early stage studies of vaccines for H1N1 and H5N1. Those studies are viewed as proof-of-concept trials to assist in the marketing of the companies' technology, DelwareOnline reports.

"Current vaccines for yellow fever are produced in chicken eggs from a live, attenuated strain of the yellow fever virus," says Vidadi Yusibov, chief scientific officer of iBio and executive director of FCMB. "We are confident our technology for producing vaccines will significantly help to protect a broader audience against this serious disease."

- get the iBio release
- check out the DelawareOnline story

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.